Target Company Overview
Extantia proudly announces its leadership in a $5.5 million funding round for Modern Synthesis, a London-based startup dedicated to revolutionizing the textile industry through advanced material science. This innovative company specializes in converting bacterial nanocellulose (BNC), a natural byproduct of fermentation, into sustainable alternatives for textiles and coatings, effectively providing cost-efficient replacements for leather and plastic-based synthetic materials across various sectors including fashion, footwear, and automotive. With this new influx of capital, Modern Synthesis aims to enhance production capabilities at its pilot facility to meet the rising demand from major fashion brands.
The pressing need for sustainable alternatives to plastic materials is underscored by growing consumer and legislative pressure. Current solutions often fall short in scalability and performance, resulting in an anticipated significant deficit in low-impact material availability in the upcoming decades. According to our “Re-Imagining the Plastics Industry” thesis, plastics contribute up to 4.5% of global greenhouse gas emissions, yet recycled plastic constitutes merely 9% of the total. The demand for environmental responsibility ensures a ripe opportunity for companies innovating in alternative materials and recycling solutions.
Industry Overview in the UK
The UK textile sector is witnessing a considerable shift as consumers increasingly seek sustainable options. As legislators push for stringent regulations on plastic usage, the market is feeling the pressure to transition towards eco-friendly alternatives. This shift is driven by an evident consumer desire for environmentally responsible products, particularly in the fashion industry, which faces a projected shortfall of 133 million tonnes of low-impact raw materials by 2030, potentially impacting up to 8% of EBIT.
With a growing awareness of sustainability's role in public policy, upcoming circularity regulations will likely require producers to adopt practices that minimize environmental impact. The need for innovative materials is critical, especially given that emissions from plastics and synthetic leathers are expected to rise substantially if current trends continue. Companies like Modern Synthesis stand at the forefront of this transformation, offering scalable biomaterials that promise to mitigate these impacts.
Modern Synthesis not only meets market demand but also addresses environmental concerns by providing alternatives that free the industry from reliance on animal-based materials and fossil fuels. The innovative use of BNC can significantly lower overall CO2 emissions associated with textile production—as high as 100 Mt CO2e per year by 2050 in the leather and footwear sectors alone—making it an effective solution in the fight against climate change.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Rationale Behind the Deal
The investment in Modern Synthesis is strategic, based on a strong conviction regarding the potential for alternative materials in the textile space. The company’s unique proprietary processes, which allow for the production of high-performance, durable, and aesthetically pleasing materials, highlight a robust pathway towards capturing market share. This funding round is vital for scaling production capabilities and responding to increasing demand from major fashion players who are keen on adopting sustainable solutions.
Moreover, the unique roll-to-roll production process employed by Modern Synthesis distinguishes it from conventional batch processing by offering increased efficiency and lower costs. This capability is crucial in meeting the industry's need for high-volume sustainable materials while ensuring that product quality remains uncompromised.
Investor Information
Extantia is committed to pioneering investments that support innovations aimed at creating an affordable, resilient, and decarbonized future. The inclusion of prominent partners like Artesian and Collab Fund further strengthens the investment round, providing Modern Synthesis with the necessary resources to accelerate its mission. The synergy among these investors reflects a shared vision of fostering sustainability through cutting-edge technologies.
Extantia’s role as a lead investor underscores its dedication to sustainability and responsible investment strategies, focusing on companies poised to tackle global challenges related to climate change and material waste. This partnership aligns perfectly with Extantia's investment philosophy of seeking out impactful technologies that can drive substantial change.
View of Dealert
In the ever-evolving landscape of sustainability and material science, Modern Synthesis represents a compelling investment opportunity. The combination of innovative technology and pressing market needs positions the company well for growth and impact. With a strong leadership team and effective biopolymer technologies, the potential for success in displacing conventional materials is promising.
Furthermore, addressing the urgent issue of environmental sustainability gives Modern Synthesis a competitive edge in capturing growing consumer demand. As regulations advance and fashion brands prioritize sustainability, the company stands to gain significantly from its early positioning in this market, making this funding round a strategic move for both the company and its investors.
Overall, the deal is seen as a vital step towards fostering innovation in the textile industry while addressing critical environmental challenges. By enabling Modern Synthesis to scale its pilot production capabilities, Extantia and its partners are paving the way for a more sustainable future, which is of paramount importance in today's climate-conscious market.
Similar Deals
Cambridge Innovation Capital, SV Health Investors’ Dementia Discovery Fund, M Ventures, Pfizer Ventures → TRIMTECH Therapeutics
2025
ACF Investors → Monument Therapeutics
2025
AlbionVC and Spark Capital → Latent Technology
2025
Extantia
invested in
Modern Synthesis
in 2023
in a Seed Stage deal
Disclosed details
Transaction Size: $6M